Please find the link for the following HIV protocol:
UPDATED CONSENSUS PROTOCOL FOR ADVANCED PANEL IMMUNOPHENOTYPING V. 3.0
Specific molecules present on the cell surface can define characteristics of lymphocytes such as
lineage-restriction, state of activation or functional capabilities. The phenotype of peripheral
blood lymphocytes can be determined using fluorochome-conjugated monoclonal antibodies and
flow cytometric techniques.
In HIV infection, changes in the size of specific phenotypically defined lymphocyte subsets relate
to stage of disease, predict rate of disease progression or indicate response to treatment.
The advanced panel immunophenotyping assay enumerates peripheral blood lymphocytes in
certain phenotypically defined subsets by determining the expression of additional surface
antigen on either CD4+ or CD8+ lymphocytes.
Separate guidelines currently exists for quantitating the major, lineage-restricted subsets of
CD3/CD4 and CD3/CD8 lymphocytes (1-3) and the importance of using CD45 gating for these
determinations. An electronic link to the current NIAID/DAIDS guideline is located on the
AACTG web site at http://aactg.s-3.com/immlab.htm under the heading, Flow Cytometry
This Version 3.0 Updated Consensus Protocol for Advanced Panel Immunophenotyping is for
quantitating additional subcategories of CD4+ or CD8+ lymphocyte lineage-restricted subsets. It
is imperative that laboratories adhere strictly to the reagents and methodology contained in
this protocol in order to minimize interlaboratory variability and to increase the precision
of these determinations.